Update On Trump’s Oval Office Medical Scare
WASHINGTON, D.C. — A dramatic moment unfolded at the White House on Thursday as President Donald Trump unveiled his groundbreaking “Most-Favored Nation” plan to cut prescription drug costs for American families.
Midway through the announcement, a pharmaceutical company representative suddenly collapsed, stunning reporters and officials in the Oval Office.
Dr. Mehmet Oz Rushed to Help
Witnesses say Dr. Mehmet Oz, who attended the event, quickly ran to the man’s aid as Secret Service and White House medical staff rushed forward. The press was immediately escorted out as medical personnel took over.
“While President Trump was delivering his Most-Favored Nation announcement in the Oval Office, one company representative suddenly fainted,” White House Press Secretary Karoline Leavitt stated. “The medical team on site acted immediately, and he’s now doing fine. The briefing will continue shortly.”
President Trump’s Concern and Calm Leadership
President Trump paused the briefing and was heard asking, “Are you OK, Gordon? Are you OK?” before calmly directing staff to assist and restore order. His composure underscored the president’s steady leadership — even in the face of the unexpected.
Security quickly instructed the media to turn off their cameras as they escorted reporters out of the room, saying, “Cameras off. Thank you, press.”
Confusion Over Identity
Early reports falsely identified the man as a global brand director for Ozempic manufacturer Novo Nordisk. However, the company later issued a statement confirming none of its employees were in attendance.
Newsmax has reached out to the White House to confirm the individual’s identity.
Trump’s Fight Against Big Pharma
The incident temporarily paused what was meant to be a major announcement by President Trump — a historic step toward lowering prescription drug prices and holding Big Pharma accountable.
The “Most-Favored Nation” initiative would ensure Americans pay no more for medications than patients in other developed nations, ending decades of price gouging and protecting seniors who have long been forced to pay more than anyone else in the world.
Trump’s proposal has been widely praised by patient advocates and American manufacturers, while Democrats and global drug conglomerates continue to resist reforms that would hurt their profits.
